prof. dr. H.G.M. (Harry) Heijerman
Full Professor
- Department of Pulmonary Diseases
Contact
Research Output (43)
Home videos of cystic fibrosis patients using tobramycin inhalation powder:Relation of flow and cough
Meerburg Jennifer J, Albasri Mehdi, van der Wiel Els C, Andrinopoulou Eleni-Rosalina, van der Eerden Menno M, Majoor Christof J, Arets Hubertus G M, Heijerman Harry G M, Tiddens Harm A W M nov 2019, In: Pediatric Pulmonology. 54 , p. 1794-1800 7 p.
Prevention of drug-related complications in cystic fibrosis
van der Meer Renske, Touw Daan J, Heijerman Harry G M nov 2019, In: Current Opinion in Pulmonary Medicine. 25 , p. 666-673 8 p.
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation:a double-blind, randomised, phase 3 trial
Heijerman Harry G M, McKone Edward F, Downey Damian G, Van Braeckel Eva, Rowe Steven M, Tullis Elizabeth, Mall Marcus A, Welter John J, Ramsey Bonnie W, McKee Charlotte M, Marigowda Gautham, Moskowitz Samuel M, Waltz David, Sosnay Patrick R, Simard Christopher, Ahluwalia Neil, Xuan Fengjuan, Zhang Yaohua, Taylor-Cousar Jennifer L, McCoy Karen S, 30 okt 2019, In: The Lancet. 394 , p. 1940-1948 9 p.
CLINICAL EFFECT OF LUMACAFTOR/IVACAFTOR IN F508DEL HOMOZYGOUS CF PATIENTS WITH FEV1 >= 90% PREDICTED AT BASELINE
Aalbers B., de Winter-de Groot K., Arets B., Hofland R., Kiviet C. D., Oirschot M., V, Kruijswijk M., Schotman S., Heida-Michel S., van der Ent K., Heijerman H. okt 2019, In: Pediatric Pulmonology. 54 , p. S342-S342
Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis:A randomized, crossover study
van Velzen Annelies J, Uges Joris W F, Heijerman Harry G M, Arets Bert G M, Nuijsink Marianne, van der Wiel-Kooij Els C, van Maarseveen Erik M, van Zanten Gijsbert A, Pullens Bas, Touw Daan J, Janssens Hettie M sep 2019, In: British Journal of Clinical Pharmacology. 85 , p. 1984-1993 10 p.
Aligning patients' needs and research priorities towards a comprehensive CF research program
Noordhoek Jacquelien J., Gulmans Vincent A.M., Heijerman Harry G.M., van der Ent Cornelis K. 1 mei 2019, In: Journal of Cystic Fibrosis. 18 , p. 382-384 3 p.
Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis
Berkers Gitte, van Mourik Peter, Vonk Annelotte M, Kruisselbrink Evelien, Dekkers Johanna F, de Winter-de Groot Karin M, Arets Hubertus G M, Marck-van der Wilt Rozemarijn E P, Dijkema Jasper S, Vanderschuren Maaike M, Houwen Roderick H J, Heijerman Harry G M, van de Graaf Eduard A, Elias Sjoerd G, Majoor Christof J, Koppelman Gerard H, Roukema Jolt, Bakker Marleen, Janssens Hettie M, van der Meer Renske, Vries Robert G J, Clevers Hans C, de Jonge Hugo R, Beekman Jeffrey M, van der Ent Cornelis K 12 feb 2019, In: Cell Reports. 26 , p. 1701-1708.e3
Specific airway resistance is a better outcome parameter in bronchial provocation testing compared to FEV1 in patients with bronchial asthma
van Nederveen-Bendien S A, Vahl J, Heijerman H G M dec 2018, In: Journal of Asthma. 55 , p. 1338-1342 5 p.
Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration
Post Titiaan E, Kamerling Ingrid M C, van Rossen Richard C J M, Burggraaf Jacobus, Stevens Jasper, Dijkmans Anneke C, Heijerman Harry G M, Touw Daan J, van Velzen Annelies J, Wilms Erik B nov 2018, In: European journal of hospital pharmacy : science and practice. 25 , p. 337-339 3 p.
Prevalence of severe fatigue among adults with cystic fibrosis:A single center study
Nap-van der Vlist Merel M., Burghard Marcella, Hulzebos H. J., Doeleman Wytze R., Heijerman Harry G.M., van der Ent Cornelis K., Nijhof Sanne L. mei 2018, In: Journal of Cystic Fibrosis. 17 , p. 368-374